DexCom Change In Cash from 2010 to 2024

DXCM Stock  USD 77.83  5.00  6.87%   
DexCom Change In Cash yearly trend continues to be very stable with very little volatility. Change In Cash is likely to grow to about -72 M this year. During the period from 2010 to 2024, DexCom Change In Cash quarterly data regression pattern had sample variance of 102908.4 T and median of  8,400,000. View All Fundamentals
 
Change In Cash  
First Reported
2005-03-31
Previous Quarter
88 M
Current Value
-316.8 M
Quarterly Volatility
181.4 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check DexCom financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DexCom's main balance sheet or income statement drivers, such as Interest Expense of 15.5 M, Other Operating Expenses of 3.2 B or Operating Income of 627.6 M, as well as many indicators such as Price To Sales Ratio of 23.64, Dividend Yield of 0.0 or PTB Ratio of 24.31. DexCom financial statements analysis is a perfect complement when working with DexCom Valuation or Volatility modules.
  
Check out the analysis of DexCom Correlation against competitors.

Latest DexCom's Change In Cash Growth Pattern

Below is the plot of the Change In Cash of DexCom Inc over the last few years. It is DexCom's Change In Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in DexCom's overall financial position and show how it may be relating to other accounts over time.
Change In Cash10 Years Trend
Very volatile
   Change In Cash   
       Timeline  

DexCom Change In Cash Regression Statistics

Arithmetic Mean32,566,096
Geometric Mean54,273,257
Coefficient Of Variation985.05
Mean Deviation202,942,603
Median8,400,000
Standard Deviation320,793,340
Sample Variance102908.4T
Range1.4B
R-Value(0.09)
Mean Square Error109831.2T
R-Squared0.01
Significance0.74
Slope(6,790,772)
Total Sum of Squares1440717.1T

DexCom Change In Cash History

2024-72 M
2023-75.8 M
2022-410.3 M
2021235.4 M
2020371.8 M
2019-690.7 M
2018695.6 M

About DexCom Financial Statements

DexCom investors utilize fundamental indicators, such as Change In Cash, to predict how DexCom Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Change In Cash-75.8 M-72 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether DexCom Inc is a strong investment it is important to analyze DexCom's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DexCom's future performance. For an informed investment choice regarding DexCom Stock, refer to the following important reports:
Check out the analysis of DexCom Correlation against competitors.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.157
Earnings Share
1.65
Revenue Per Share
10.089
Quarterly Revenue Growth
0.02
Return On Assets
0.0606
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.